Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199.

Shihui MaoQing LingJiajia PanFenglin LiShujuan HuangWenle YeWenwen WeiXiangjie LinYu QianYungui WangXin HuangJiansong HuangJinghan WangJie Jin

Published in: Journal of translational medicine (2021)

Our study indicates that overexpression of CPT1a predicts poor clinical outcome in AML. CPT1a-selective inhibitor ST1326 combined with Bcl-2 inhibitor ABT199 showed strong synergistic inhibitory effects on AML.

Keyphrases

acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
cell proliferation
transcription factor
cancer therapy